PF-04957325

Research use only, not for human use.

PF-04957325 is a potent and selective inhibitor of PDE8.PF-04957325 has an IC50 of 0.7 nM for PDE8A and 0.3 nM for PDE8B.PF-04957325 can be used to study autoimmune encephalomyelitis.

PF-04957325 is a highly potent and selective PDE8 inhibitor, with IC50s of 0.7 nM and 0.3 nM for PDE8A and PDE8B, respectively.

PF-04957325 is over two orders of magnitude less efficient than PICL in suppressing polyclonal Teff cell proliferation, and shows no effect on cytokine gene expression in these cells, despite its robust effect on T cell adhesion. PF-04957325 is a selective PDE8 inhibitor and inhibits breast cancer cell migration. PF-04957325 greatly potentiates steroidogenesis in WT adrenal cells. PF-04957325 shows a reported IC50 of 0.7 nM against PDE8A, 0.2 nM against PDE8B, and > 1.5 μM against all other PDE isoforms. PF-04957325 treatment of WT Leydig cells or MA10 cells increases steroid production but has no effect in PDE8A (-/-)/B(-/-) double-knockout cells, confirming the selectivity of the drug. Moreover, under basal conditions, cotreatment with PF-04957325 plus rolipram, a PDE4-selective inhibitor, synergistically potentiates steroid production.

——

——

Angiogenesis

PDE

PDE

——

——

1305115-80-3

400.38

C14H15F3N8OS

>98% (HPLC)

In Vitro:?DMSO : ≥ 100 mg/mL (249.76 mM )

Nc1nc(nc2n(C[C@H]3CN(Cc4nccs4)CCO3)nnc12)C(F)(F)F

——

(-20℃)

With Ice Pack

≥ 2 years